Latest Breaking News On - Phase 3 karmma trial nct03651128 - Page 1 : vimarsana.com

Sagar Lonial, MD, FACP, details additional agents of interest outside CAR T-cell therapies in multiple myeloma including the recently approved agents elranatamab and talquetamab.

Cancer at emory university school of medicineDepartment of hematologySagar lonialNew england journalMedical oncologyBernard gray family chairEmory university schoolRelapsed refractory multiple myelomaCart cell therapiesIdecabtagene vicleucelCiltacabtagene autoleucelPhase 3 karmma trial nct03651128Phase 3 cartitude 4 trial nct04181827Bispecifict cell engagers